Noscira, a company of Zeltia group devoted to the research and development of innovative drugs for the treatment of diseases of the nervous system, has received the approval of the Austrian health authorities and the Ethics Committee for the initiation of the first Phase II study with NP-12 for the treatment of Alzheimer’s disease. NP-12, the first compound of Noscira’s product pipeline, is an innovative drug of a new family of compounds.

More: continued here

This entry was posted on Tuesday, October 28th, 2008 at 5:10 pm and is filed under Alzheimer's / Dementia News XML/RSS Feed. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.